Skip to main content
SpringerLink
Log in

Clinical Detection and Treatment of Parathyroid Diseases

  • Chapter
  • First Online:
Book cover Molecular Pathology of Endocrine Diseases

Part of the book series: Molecular Pathology Library ((MPLB,volume 3))

  • 902 Accesses

Abstract

Parathyroid pathology is usually manifested clinically as hyperparathyroidism (HPT), resulting from parathormone (PTH) excess. PTH is the chief hormone product of the parathyroid glands and can be overproduced in several complexly interrelated settings, termed primary (PHPT), secondary (SHPT), and tertiary hyperparathyroidism (THPT). PHPT can arise sporadically or from inherited syndromes that include multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2A (MEN2A), isolated familial hyperparathyroidism (FHPT), and familial hyperparathyroidism-jaw tumor syndrome (FHJT). SHPT is secondary to hypocalcemia, renal insufficiency, and/or severe vitamin D deficiency. THPT by definition occurs with a history of renal failure and long-standing SHPT.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McPhaul JJ Jr, McIntosh DA, Hammond WS, et al. Autonomous secondary (renal) parathyroid hyperplasia. N Engl J Med. 1964;271:1342–1345.

    Article  PubMed  Google Scholar 

  2. van Heerden JA, Grant CS. Surgical treatment of primary hyperparathyroidism: an institutional perspective. World J Surg. 1991;15(6):688–692.

    Article  PubMed  Google Scholar 

  3. Kaplan EL, Yashiro T, Salti G. Primary hyperparathyroidism in the 1990s. Choice of surgical procedures for this disease. Ann Surg. 1992;215(4):300–317.

    Article  PubMed  CAS  Google Scholar 

  4. Weber CJ, Sewell CW, McGarity WC. Persistent and recurrent sporadic primary hyperparathyroidism: histopathology, complications, and results of reoperation. Surgery. 1994;116(6):991–998.

    PubMed  CAS  Google Scholar 

  5. Molinari AS, Irvin GL 3rd, Deriso GT, et al. Incidence of multiglandular disease in primary hyperparathyroidism determined by parathyroid hormone secretion. Surgery. 1996;120(6):934–936.

    Article  PubMed  CAS  Google Scholar 

  6. Kebebew E, Clark OH. Parathyroid adenoma, hyperplasia, and carcinoma: localization, technical details of primary neck exploration, and treatment of hypercalcemic crisis. Surg Oncol Clin N Am. 1998;7(4):721–748.

    PubMed  CAS  Google Scholar 

  7. Lee NC, Norton JA. Multiple-gland disease in primary hyperparathyroidism: a function of operative approach? Arch Surg. 2002;137(8):896–899.

    Article  PubMed  Google Scholar 

  8. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658–5671.

    Article  PubMed  CAS  Google Scholar 

  9. Kebebew E, Duh QY, Clark OH. Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy. Arch Surg. 2004;139(9):974–977.

    Article  PubMed  Google Scholar 

  10. Sahasranam P, Tran MT, Mohamed H, Friedman TC. Multiglandular parathyroid carcinoma: a case report and brief review. South Med J. 2007;100(8):841–844.

    PubMed  Google Scholar 

  11. Akerström G, Malmaeus J, Bergström R. Surgical anatomy of human parathyroid glands. Surgery. 1984;95(1):14–21.

    PubMed  Google Scholar 

  12. Brown EM. The pathophysiology of primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N24-N29.

    PubMed  CAS  Google Scholar 

  13. Bilezikian JP, Potts JT Jr. Asymptomatic primary hyperparathyroidism: new issues and new questions - bridging the past with the future. J Bone Miner Res. 2002;17(suppl 2):N57-N67.

    PubMed  Google Scholar 

  14. Silverberg SJ, Shane E, Jacobs TP, et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med. 1990;89(3):327–334.

    Article  PubMed  CAS  Google Scholar 

  15. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341(17):1249–1255.

    Article  PubMed  CAS  Google Scholar 

  16. Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res. 2002;17(suppl 2):N87-N94.

    PubMed  CAS  Google Scholar 

  17. Silverberg SJ. Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N117-N125.

    PubMed  Google Scholar 

  18. Stefenelli T, Abela C, Frank H, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab. 1997;82(1):106–112.

    Article  PubMed  CAS  Google Scholar 

  19. Piovesan A, Molineri N, Casasso F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf). 1999;50(3):321–328.

    Article  CAS  Google Scholar 

  20. Leifsson BG, Ahrén B. Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab. 1996;81(6):2149–2153.

    Article  PubMed  CAS  Google Scholar 

  21. Vestergaard P, Mollerup CL, Frøkjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg. 2003;27(2):216–222.

    PubMed  Google Scholar 

  22. Parisien M, Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. Bone disease in primary hyperparathyroidism. Endocrinol Metab Clin North Am. 1990;19(1):19–34.

    PubMed  CAS  Google Scholar 

  23. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 1989;4(3):283–291.

    Article  PubMed  CAS  Google Scholar 

  24. Miller PD, Bilezikian JP. Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N98-N102.

    PubMed  Google Scholar 

  25. Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O’Fallon W, Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14(10):1700–1707.

    Article  PubMed  CAS  Google Scholar 

  26. Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81(11):4007–4012.

    Article  PubMed  CAS  Google Scholar 

  27. Patten BM, Bilezikian JP, Mallette LE, Prince A, Engel WK, Aurbach GD. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med. 1974;80(2):182–193.

    PubMed  CAS  Google Scholar 

  28. Turken SA, Cafferty M, Silverberg SJ, et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med. 1989;87(5):553–557.

    Article  PubMed  CAS  Google Scholar 

  29. Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg. 1995;222(3):402–412.

    Article  PubMed  CAS  Google Scholar 

  30. Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg. 1998;22(6):513–518.

    Article  PubMed  CAS  Google Scholar 

  31. Talpos GB, Bone HG 3rd, Kleerekoper M, et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery. 2000;128(6):1013–1020.

    Article  PubMed  CAS  Google Scholar 

  32. Sywak MS, Knowlton ST, Pasieka JL, Parsons LL, Jones J. Do the National Institutes of Health consensus guidelines for parathyroidectomy predict symptom severity and surgical outcome in patients with primary hyperparathyroidism? Surgery. 2002;132(6):1013–1019.

    Article  PubMed  Google Scholar 

  33. Pasieka JL, Parsons LL, Demeure MJ, et al. Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism. World J Surg. 2002;26(8):942–949.

    Article  PubMed  Google Scholar 

  34. Kleerekoper M, Bilezkian JP. A cure in search of a disease: parathyroidectomy for nontraditional features of primary hyperparathyroidism. Am J Med. 1994;96(2):99–100.

    Article  PubMed  CAS  Google Scholar 

  35. Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81(6):2036–2040.

    Article  PubMed  CAS  Google Scholar 

  36. Mazzaglia PJ, Berber E, Kovach A, Milas M, Esselstyn C, Siperstein AE. The changing presentation of hyperparathyroidism over 3 decades. Arch Surg. 2008;143(3):260–266.

    Article  PubMed  Google Scholar 

  37. Clark OH. “Asymptomatic” primary hyperparathyroidism: is parathyroidectomy indicated? Surgery. 1994;116(6):947–953.

    PubMed  CAS  Google Scholar 

  38. Heath H 3rd, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980;302(4):189–193.

    Article  PubMed  Google Scholar 

  39. Wermers RA, Khosla S, Atkinson EJ, Hodgson SF, O’Fallon WM, Melton LJ 3rd. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med. 1997;126(6):433–440.

    PubMed  CAS  Google Scholar 

  40. Mundy GR, Cove DH, Fisken R. Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet. 1980;1(8182):1317–1320.

    Article  PubMed  CAS  Google Scholar 

  41. Heath H 3rd. Primary hyperparathyroidism: recent advances in pathogenesis, diagnosis, and management. Adv Intern Med. 1992;37:275–293.

    PubMed  Google Scholar 

  42. Melton LJ 3rd. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 2002;17(suppl 2):N12-N17.

    PubMed  Google Scholar 

  43. National Institutes of Health Consensus Development Conference. Diagnosis and management of asymptomatic primary hyperparathyroidism. Consens Statement. October 29-31, 1990;8:1–18.

    Google Scholar 

  44. Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 2002;87(12):5353–5361.

    Article  PubMed  CAS  Google Scholar 

  45. Jüppner H, Potts JT Jr. Immunoassays for the detection of parathyroid hormone. J Bone Miner Res. 2002;17(suppl 2):N81-N86.

    PubMed  Google Scholar 

  46. Endres DB, Villanueva R, Sharp CF Jr, Singer FR. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem. 1991;37(2):162–168.

    PubMed  CAS  Google Scholar 

  47. Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res. 2007;22(suppl 2):V100-V104.

    Article  PubMed  CAS  Google Scholar 

  48. Burtis WJ, Fodero JP, Gaich G, Debeyssey M, Stewart AF. Preliminary characterization of circulating amino- and carboxy-terminal fragments of parathyroid hormone-related peptide in humoral hypercalcemia of malignancy. J Clin Endocrinol Metab. 1992;75(4):1110–1114.

    Article  PubMed  CAS  Google Scholar 

  49. Pollak MR, Brown EM, Chou YH, et al. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell. 1993;75(7):1297–1303.

    Article  PubMed  CAS  Google Scholar 

  50. Fuleihan Gel-H. Familial benign hypocalciuric hypercalcemia. J Bone Miner Res. 2002;17(suppl 2):N51-N56.

    CAS  Google Scholar 

  51. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 1994;23(2):229–236.

    PubMed  CAS  Google Scholar 

  52. Llach F, Velasquez Forero F. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis. 2001;38(5 suppl 5):S20-S33.

    Article  PubMed  CAS  Google Scholar 

  53. Tominaga Y. Mechanism of parathyroid tumourigenesis in uraemia. Nephrol Dial Transplant. 1999;14(suppl 1):63–65.

    Article  PubMed  Google Scholar 

  54. Alfrey AC, Jenkins D, Groth CG, Schorr WS, Gecelter L, Ogden DA. Resolution of hyperparathyroidism, renal osteodystrophy and metastatic calcification after renal homotransplantation. N Engl J Med. 1968;279(25):1349–1356.

    Article  PubMed  CAS  Google Scholar 

  55. Latimer RG, Renning J, Stevens LE, Northway JD, Reemtsma K. Tertiary hyperparathyroidism following successful renal allografting. Ann Surg. 1970;172(1):137–141.

    PubMed  CAS  Google Scholar 

  56. Karstrup S, Hegedüs L, Holm HH. Ultrasonically guided chemical parathyroidectomy in patients with primary hyperparathyroidism: a follow-up study. Clin Endocrinol (Oxf). 1993;38(5):523–530.

    Article  CAS  Google Scholar 

  57. AACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract. 2005;11(1):49–54.

    Google Scholar 

  58. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93(9):3462–3470.

    Article  PubMed  CAS  Google Scholar 

  59. Silverberg SJ, Brown I, Bilezikian JP. Age as a criterion for surgery in primary hyperparathyroidism. Am J Med. 2002;113(8):681–684.

    Article  PubMed  Google Scholar 

  60. Eigelberger MS, Cheah WK, Ituarte PH, Streja L, Duh QY, Clark OH. The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited? Ann Surg. 2004;239(4):528–535.

    Article  PubMed  Google Scholar 

  61. Sosa JA, Powe NR, Levine MA, Udelsman R, Zeiger MA. Profile of a clinical practice: thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. J Clin Endocrinol Metab. 1998;83(8):2658–2665.

    Article  PubMed  CAS  Google Scholar 

  62. Sosa JA, Powe NR, Levine MA, Bowman HM, Zeiger MA, Udelsman R. Cost implications of different surgical management strategies for primary hyperparathyroidism. Surgery. 1998;124(6):1028–1035.

    Article  PubMed  CAS  Google Scholar 

  63. Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery. 2006;140(6):874–881.

    Article  PubMed  Google Scholar 

  64. Burney RE, Jones KR, Coon JW, Blewitt DK, Herm AM. Assessment of patient outcomes after operation for primary hyperparathyroidism. Surgery. 1996;120(6):1013–1018.

    Article  PubMed  CAS  Google Scholar 

  65. Burney RE, Jones KR, Peterson M, Christy B, Thompson NW. Surgical correction of primary hyperparathyroidism improves quality of life. Surgery. 1998;124(6):987–991.

    PubMed  CAS  Google Scholar 

  66. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med. 2004;350(17):1746–1751.

    Article  PubMed  CAS  Google Scholar 

  67. Cosman F, Shen V, Xie F, Seibel M, Ratcliffe A, Lindsay R. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers. Ann Intern Med. 1993;118(5):337–343.

    PubMed  CAS  Google Scholar 

  68. Marcus R. The role of estrogens and related compounds in the management of primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N146-N149.

    PubMed  CAS  Google Scholar 

  69. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88(3):1174–1178.

    Article  PubMed  CAS  Google Scholar 

  70. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 2001;16(1):113–119.

    Article  PubMed  CAS  Google Scholar 

  71. Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88(2):581–587.

    Article  PubMed  CAS  Google Scholar 

  72. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366(6455):575–580.

    Article  PubMed  CAS  Google Scholar 

  73. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998;95(7):4040–4045.

    Article  PubMed  CAS  Google Scholar 

  74. Nemeth EF, Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab. 1999;10(2):66–71.

    Article  PubMed  CAS  Google Scholar 

  75. Antoniucci DM, Shoback D. Calcimimetics in the treatment of primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N141-N145.

    PubMed  CAS  Google Scholar 

  76. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88(12):5644–5649.

    Article  PubMed  CAS  Google Scholar 

  77. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90(1):135–141.

    Article  PubMed  CAS  Google Scholar 

  78. Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism. 2008;57(4):517–521.

    Article  PubMed  CAS  Google Scholar 

  79. Siperstein A, Berber E, Mackey R, et al. Prospective evaluation of sestamibi scan, ultrasonography, and rapid PTH to predict the success of limited exploration for sporadic primary hyperparathyroidism. Surgery. 2004;136(4):872–880.

    Article  PubMed  Google Scholar 

  80. Arici C, Cheah WK, Ituarte PH, et al. Can localization studies be used to direct focused parathyroid operations? Surgery. 2001;129(6):720–729.

    Article  PubMed  CAS  Google Scholar 

  81. Quiros RM, Alioto J, Wilhelm SM, et al. An algorithm to maximize use of minimally invasive parathyroidectomy. Arch Surg. 2004;139(5):501–506.

    Article  PubMed  Google Scholar 

  82. Berri RN, Lloyd LR. Detection of parathyroid adenoma in patients with primary hyperparathyroidism: the use of office-based ultrasound in preoperative localization. Am J Surg. 2006;191(3):311–314.

    Article  PubMed  Google Scholar 

  83. Solorzano CC, Carneiro-Pla DM, Irvin GL 3rd. Surgeon-performed ultrasonography as the initial and only localizing study in sporadic primary hyperparathyroidism. J Am Coll Surg. 2006;202(1):18–24.

    Article  PubMed  Google Scholar 

  84. Yip L, Pryma DA, Yim JH, et al. Sestamibi SPECT intensity scoring system in sporadic primary hyperparathyroidism. World J Surg. 2009;33(3):426–433.

    Article  PubMed  Google Scholar 

  85. Yip L, Pryma DA, Yim JH, et al. Can a lightbulb sestamibi SPECT accurately predict single-gland disease in sporadic primary hyperparathyroidism? World J Surg. 2008;32(5):784–792.

    Article  PubMed  Google Scholar 

  86. Doherty GM, Weber B, Norton JA. Cost of unsuccessful surgery for primary hyperparathyroidism. Surgery. 1994;116(6):954–957.

    PubMed  CAS  Google Scholar 

  87. Irvin GL 3rd, Carneiro DM, Solorzano CC. Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Ann Surg. 2004;239(5):704–708.

    Article  PubMed  Google Scholar 

  88. Irvin GL 3rd, Sfakianakis G, Yeung L, et al. Ambulatory parathyroidectomy for primary hyperparathyroidism. Arch Surg. 1996;131(10):1074–1078.

    PubMed  Google Scholar 

  89. Boggs JE, Irvin GL 3rd, Molinari AS, Deriso GT. Intraoperative parathyroid hormone monitoring as an adjunct to parathyroidectomy. Surgery. 1996;120(6):954–958.

    Article  PubMed  CAS  Google Scholar 

  90. Carty SE, Worsey J, Virji MA, Brown ML, Watson CG. Concise parathyroidectomy: the impact of preoperative SPECT 99mTc sestamibi scanning and intraoperative quick parathormone assay. Surgery. 1997;122(6):1107–1114.

    Article  PubMed  CAS  Google Scholar 

  91. Molinari AS, Irvin GL 3rd, Deriso GT, Bott L. Incidence of multiglandular disease in primary hyperparathyroidism determined by parathyroid hormone secretion. Surgery. 1996;120(6):934–936.

    Article  PubMed  CAS  Google Scholar 

  92. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 2002;235(5):665–670.

    Article  PubMed  Google Scholar 

  93. Karakousis GC, Han D, Kelz RR, et al. Interpretation of intra-operative PTH changes in patients with multi-glandular primary hyperparathyroidism (pHPT). Surgery. 2007;142(6):845–850.

    Article  PubMed  Google Scholar 

  94. Miura D, Wada N, Arici C, Morita E, Duh QY, Clark OH. Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy? World J Surg. 2002;26(8):926–930.

    Article  PubMed  Google Scholar 

  95. Carchman E, Ogilvie J, Holst J, Yim J, Carty S. Appropriate surgical treatment of lithium-associated hyperparathyroidism. World J Surg. 2008;32(10):2195–2199.

    Article  PubMed  Google Scholar 

  96. Duh QY, Arnaud CD, Levin KE, Clark OH. Parathyroid hormone: before and after parathyroidectomy. Surgery. 1986;100(6):1021–1031.

    PubMed  CAS  Google Scholar 

  97. Koivunen DG, Buick MK, Seaton JF, Harrison TS. Early postoperative function of suppressed parathyroid glands with microscopic hyperplasia. Surgery. 1986;100(6):1011–1020.

    PubMed  CAS  Google Scholar 

  98. Lundgren E, Rastad J, Ridefelt P, Juhlin C, Akerström G, Ljunghall S. Long-term effects of parathyroid operation on serum calcium and parathyroid hormone values in sporadic primary hyperparathyroidism. Surgery. 1992;112(6):1123–1129.

    PubMed  CAS  Google Scholar 

  99. Bergenfelz A, Valdemarsson S, Tibblin S. Persistent elevated serum levels of intact parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of detrimental effects of severe parathyroid disease. Surgery. 1996;119(6):24–633.

    Article  PubMed  CAS  Google Scholar 

  100. Tisell LE, Jansson S, Nilsson B, Lundberg PA, Lindstedt G. Transient rise in intact parathyroid hormone concentration after surgery for primary hyperparathyroidism. Br J Surg. 1996;83(5):665–669.

    Article  PubMed  CAS  Google Scholar 

  101. Mandal AK, Udelsman R. Secondary hyperparathyroidism is an expected consequence of parathyroidectomy for primary hyperparathyroidism: a prospective study. Surgery. 1998;124(6):1021–1026.

    Article  PubMed  CAS  Google Scholar 

  102. Denizot A, Pucini M, Chagnaud C, Botti G, Henry JF. Normocalcemia with elevated parathyroid hormone levels after surgical treatment of primary hyperparathyroidism. Am J Surg. 2001;182(1):15–19.

    Article  PubMed  CAS  Google Scholar 

  103. Carty SE, Roberts MM, Virji MA, Haywood L, Yim JH. Elevated serum parathormone level after “concise parathyroidectomy” for primary sporadic hyperparathyroidism. Surgery. 2002;132(6):1086–1092.

    Article  PubMed  Google Scholar 

  104. Bruining HA, Birkenhäger JC, Ong GL, Lamberts SW. Causes of failure in operations for hyperparathyroidism. Surgery. 1987;101(5):562–565.

    PubMed  CAS  Google Scholar 

  105. Boggs JE, Irvin GL 3rd, Carneiro DM, Molinari AS. The evolution of parathyroidectomy failures. Surgery. 1999;126(6):998–1002.

    PubMed  CAS  Google Scholar 

  106. Carty SE. Prevention and management of complications in parathyroid surgery. Otolaryngol Clin North Am. 2004;37(4):897–907.

    Article  PubMed  Google Scholar 

  107. Wells SA Jr, Debenedetti MK, Doherty GM. Recurrent or persistent hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N158-N162.

    PubMed  Google Scholar 

  108. Carty SE, Helm AK, Amico JA, et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery. 1998;124(6):1106–1113.

    Article  PubMed  CAS  Google Scholar 

  109. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404–407.

    Article  PubMed  CAS  Google Scholar 

  110. Yip L, Ogilvie JB, Challinor SM, et al. Identification of multiple endocrine neoplasia type 1 in patients with apparent sporadic primary hyperparathyroidism. Surgery. 2008;144(6):1002–1006.

    Article  PubMed  Google Scholar 

  111. Marx SJ, Simonds WF, Agarwal SK, et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res. 2002;17(suppl 2):N37-N43.

    PubMed  CAS  Google Scholar 

  112. O’Riordain DS, O’Brien T, Grant CS, Weaver A, Gharib H, van Heerden JA. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery. 1993;114(6):1031–1037.

    PubMed  Google Scholar 

  113. Kraimps JL, Duh QY, Demeure M, Clark OH. Hyperparathyroidism in multiple endocrine neoplasia syndrome. Surgery. 1992;112(6):1080–1086.

    PubMed  CAS  Google Scholar 

  114. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32(4):676–680.

    Article  PubMed  CAS  Google Scholar 

  115. Simonds WF, James-Newton LA, Agarwal SK, et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore). 2002;81(1):1–26.

    Article  Google Scholar 

  116. Jackson CE, Norum RA, Boyd SB, et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery. 1990;108(6):1006–1012.

    PubMed  CAS  Google Scholar 

  117. McCoy KL, Yim JH, Zuckerbraun BS, et al. Cystic parathyroid lesions: functional and nonfunctional parathyroid cysts. Arch Surg. 2009;144(1):52-56.

    Article  PubMed  Google Scholar 

  118. Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab. 2007;92(10):3803–3808.

    Article  PubMed  CAS  Google Scholar 

  119. Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int. 2000;57(1):282–292.

    Article  PubMed  CAS  Google Scholar 

  120. Sturtevant JM, Hawley CM, Reiger K, et al. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Nephrology. 2004;9(6):406–413.

    Article  PubMed  CAS  Google Scholar 

  121. Joy MS, Finn WF, LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003;42(1):96–107.

    Article  PubMed  CAS  Google Scholar 

  122. Martin KJ, González EA. Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis. 2001;38(5 suppl 5):S34-S40.

    Article  PubMed  CAS  Google Scholar 

  123. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 suppl 3):S1-S201.

    Google Scholar 

  124. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(5 suppl 2):34–38.

    Article  PubMed  Google Scholar 

  125. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–1525.

    Article  PubMed  CAS  Google Scholar 

  126. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67(2):760–771.

    Article  PubMed  CAS  Google Scholar 

  127. Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68(4):1793–1800.

    Article  PubMed  CAS  Google Scholar 

  128. Schaefer RM, Bover J, Dellanna F, et al. Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study. Clin Nephrol. 2008;70(2):126–134.

    PubMed  CAS  Google Scholar 

  129. D’Alessandro AM, Melzer JS, Pirsch JD, et al. Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery. 1989;106(6):1049–1055.

    PubMed  Google Scholar 

  130. Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19(5):1281–1287.

    Article  PubMed  CAS  Google Scholar 

  131. Kerby JD, Rue LW, Blair H, et al. Operative treatment of tertiary hyperparathyroidism: a single-center experience. Ann Surg. 1998;227(6):878–886.

    Article  PubMed  CAS  Google Scholar 

  132. Rothmund M, Wagner PK, Schark C. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg. 1991;15(6):745–750.

    Article  PubMed  CAS  Google Scholar 

  133. Lorenz K, Ukkat J, Sekulla C, et al. Total parathyroidectomy without autotransplantation for renal hyperparathyroidism: experience with a qPTH-controlled protocol. World J Surg. 2006;30(5):743–751.

    Article  PubMed  Google Scholar 

  134. Triponez F, Dosseh D, Hazzan M, et al. Subtotal parathyroidectomy with thymectomy for autonomous hyperparathyroidism after renal transplantation. Br J Surg. 2005;92(10):1282–1287.

    Article  PubMed  CAS  Google Scholar 

  135. Takagi H, Tominaga Y, Uchida K, et al. Subtotal versus total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann Surg. 1984;200(1):18–23.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Endocrine Surgery, Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, VA Pittsburg Healthcare System, Pittsburgh, PA, USA

    Michael T. Stang MD (Assistant Professor of Surgery)

  2. Section of Endocrine Surgery, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Sally E. Carty MD (Professor of Surgery)

Authors
  1. Michael T. Stang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sally E. Carty MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pathology Service, WRN202, Massachusetts General Hospital, Fruit Street 55, Boston, 02114, USA

    Jennifer L. Hunt

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Stang, M.T., Carty, S.E. (2010). Clinical Detection and Treatment of Parathyroid Diseases. In: Hunt, J. (eds) Molecular Pathology of Endocrine Diseases. Molecular Pathology Library, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-1707-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1707-2_14

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-1706-5

  • Online ISBN: 978-1-4419-1707-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation